The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| COYA | +1.51% | N/A | N/A | +18% |
| S&P | +15.66% | +86.6% | +13.29% | +80% |
Coya Therapeutics, Inc. is a clinical-stage biotechnology company which engages in developing proprietary medicinal products to modulate the function of regulatory T cells. The company was founded by Howard Berman in 2020 and is headquartered in Houston, TX.
No news articles found for Coya Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.56M | 0.0% |
| Gross Profit | $3.56M | 52101.4% |
| Gross Margin | 99.81% | 0.0% |
| Market Cap | $95.33M | -2.9% |
| Market Cap / Employee | $11.92M | 0.0% |
| Employees | 8 | 0.0% |
| Net Income | -$2,115.83K | 47.4% |
| EBITDA | -$1,910.06K | 57.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $28.13M | -9.4% |
| Accounts Receivable | $0.00K | -100.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -54.54% | -9.4% |
| Return On Invested Capital | -94.18% | 14.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,130.60K | 79.3% |
| Operating Free Cash Flow | -$1,130.60K | 79.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.72 | 2.73 | 2.88 | 3.37 | 20.93% |
| Price to Sales | 26.94 | 29.36 | 227.11 | 23.92 | 132.76% |
| Price to Tangible Book Value | 2.72 | 2.73 | 2.88 | 3.37 | 20.93% |
| Enterprise Value to EBITDA | -14.09 | -9.47 | -10.36 | -35.21 | 133.07% |
| Return on Equity | -39.6% | -52.0% | -64.0% | -62.2% | 22.33% |
| Total Debt | $0.00K | $0.00K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
